Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study

Morgan Birabaharan; Eddie Hill; Maedha Begur; David C Kaelber; Thomas C S Martin; Sanjay R Mehta

doi:10.1093/cid/ciac894

Cardiovascular Outcomes After Tixagevimab and Cilgavimab use for Pre-Exposure Prophylaxis Against Coronavirus Disease 2019: A Population-Based Propensity-matched Cohort Study

Clin Infect Dis. 2023 Apr 17;76(8):1500-1503. doi: 10.1093/cid/ciac894.

Authors

Morgan Birabaharan¹, Eddie Hill¹, Maedha Begur¹, David C Kaelber^{2

3}, Thomas C S Martin^{1

4}, Sanjay R Mehta^{1

4}

Affiliations

¹ Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California, San Diego, La Jolla, California, USA.
² The Center for Clinical Informatics Research and Education, The MetroHealth System, Cleveland, OH, USA.
³ Departments of Internal Medicine, Pediatrics, and Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
⁴ San Diego Veterans Affairs Healthcare System, San Diego, California, USA.

PMID: 36380460
DOI: 10.1093/cid/ciac894

Abstract

Tixagevimab and cilgavimab treatment was associated with higher rates of cardiovascular events in a post hoc analysis of a phase 3 trial. In this large population-based propensity-matched study, we found no increased risk of cardiovascular events up to 90 days after tixagevimab and cilgavimab administration, including in patients with pre-existing cardiovascular disease.

Keywords: COVID 19; cardiovascular; cilgavimab; evusheld; tixagevimab.

Publication types

Clinical Trial, Phase III

MeSH terms

COVID-19* / prevention & control
Cardiovascular Diseases* / epidemiology
Cardiovascular Diseases* / prevention & control
Cohort Studies
Humans
Pre-Exposure Prophylaxis*

Substances

cilgavimab
tixagevimab